NANETS Symposium | Conference

Dr. El-Rayes on the Efficacy of Tidutamab in Advanced NETs

November 18th 2021

Bassel El-Rayes, MD, discusses the efficacy of tidutamab in advanced neuroendocrine tumors.

Dr. Kunz on the Importance of Tailoring Treatments to Patients With NETs

November 18th 2021

Pamela Kunz, MD, discusses the importance of tailoring treatments to individual patients with neuroendocrine tumors.

Dr. Li on the Interim Results of a Phase 1 Trial With Surufatinib in NETs

November 17th 2021

Daneng Li, MD, discusses the interim analysis results of a phase 1 trial evaluating surufatinib in United States patients with neuroendocrine tumors.

Dr. Reidy-Lagunes on the Results of the SPINET Study by Tumor Subtype in BP-NETs

November 17th 2021

Diane Reidy-Lagunes, MD, discusses the results of the phase 3 SPINET trial by tumor subtype in bronchopulmonary neuroendocrine tumors.

Dr. Raj on Injection Site Pain With Octreotide Long-Acting Release Vs Lanreotide in NETs

November 16th 2021

Nitya Raj, MD, discusses the results of a phase 4 trial comparing injection site pain with octreotide long-acting release vs lanreotide in well-differentiated neuroendocrine tumors.

Dr. Halperin on the Efficacy of the Protocol PEN-221-001 Study in Advanced GI NETs

November 16th 2021

Daniel M. Halperin, MD, discusses the efficacy and safety results of the phase 1/2a Protocol PEN-221-001 trial in advanced gastrointestinal mid-gut neuroendocrine tumors.

Surufatinib Shows Comparable HRQoL Vs Placebo in Advanced Neuroendocrine Tumors

November 16th 2021

Surufatinib demonstrated a comparable health-related quality of life with placebo in patients with advanced neuroendocrine tumors.

Tidutamab Shows Early Tolerability, Active Immune Profile in Advanced Neuroendocrine Tumors

November 15th 2021

Tidutamab was found to be well tolerated with a best overall response of stable disease in patients with advanced, well-differentiated neuroendocrine tumors of pancreatic, gastrointestinal, lung and undetermined origin.

Pembrolizumab/Chemo Not Effective in Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas

November 15th 2021

The combination of pembrolizumab (Keytruda) and irinotecan- or paclitaxel-based chemotherapy was not found to be effective in pretreated, biomarker-unselected patients with extrapulmonary poorly differentiated neuroendocrine carcinomas.

Telotristat Ethyl Improves Symptoms and Patient Satisfaction in Carcinoid Syndrome

November 15th 2021

Patients with carcinoid syndrome reported improved symptoms following treatment with telotristat ethyl.

Elimination of Perioperative Octreotide Does Not Increase Rate or Duration of Carcinoid Crisis in NETs

November 14th 2021

Prophylactic octreotide can be safely discontinued in patients with neuroendocrine tumors undergoing operation, as stopping its use has not been shown to increase the rate or duration of carcinoid crisis.

Surufatinib/Toripalimab Combo Elicits Encouraging Efficacy in Advanced Neuroendocrine Carcinoma

November 13th 2021

The combination of surufatinib and toripalimab demonstrated promising clinical activity with a manageable safety profile when used as second-line treatment for patients with advanced neuroendocrine carcinoma.

Surufatinib Induces Robust Responses in US Patients with Extrapancreatic and Pancreatic NETs

November 12th 2021

Surufatinib demonstrated strong antitumor activity along with a manageable safety profile in heavily treated US patients with progressive extrapancreatic neuroendocrine tumors or pancreatic NETs, according to interim phase 1 data.

Lanreotide Demonstrates Confirmed Efficacy in Advanced Bronchopulmonary NETs

November 11th 2021

Lanreotide autogel/depot administered at 120 mg every 28 days may be an appropriate treatment for patients with advanced bronchopulmonary neuroendocrine tumors.

PEN-221 Demonstrates Clinical Benefit in Gastrointestinal NETs

November 10th 2021

The small molecule drug conjugate PEN-221 was generally well tolerated and elicited significant clinical benefit in patients with pretreated gastrointestinal neuroendocrine tumors.

XmAb18087 Shows Encouraging Preliminary Activity in NETs

October 3rd 2020

XmAb18087 demonstrated a disease control rate of 43% across dose levels in patients with neuroendocrine tumors and a favorable safety profile.

Novel Somatostatin Analog Shows Early Activity in Metastatic NETs, Irrespective of Primary Tumor Site

October 3rd 2020

The novel somatostatin analog for the Targeted Alpha-emitter Therapy 212Pb-DOTAMTATE has demonstrated early efficacy and a tolerable safety profile in a small cohort of patients with metastatic somatostatin receptor–expressing neuroendocrine tumors irrespective of location of the primary tumor.

Dr. Chauhan on Key Recent Advances in Neuroendocrine Tumors

October 3rd 2020

Aman Chauhan, MD, a medical oncologist at the University of Kentucky, discusses key recent advances in therapeutics for patients with neuroendocrine tumors, and points to the future with ongoing combination studies.

Increased Lanreotride Autogel Dosing Shows Encouraging Antitumor Activity in Progressive Pancreatic, Midguts NETs

October 3rd 2020

Increasing the dosage of lanreotide autogel from every 28 days to every 14 days led to encouraging progression-free survival outcomes in patients with progressive pancreatic and midgut neuroendocrine tumors.

Dr. Strosberg on Retreatment With Lutathera in Advanced NETs

October 3rd 2020

Jonathan Strosberg, MD, discusse​s retreatment with Lutathera in advanced neuroendocrine tumors.

NEXT PAGE
PREVIOUS PAGE